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Parkinson’s Disease (PD) is a prototypical basal ganglia disorder. Nigrostriatal
dopaminergic denervation leads to progressive dysfunction of the cortico-basal ganglia-
thalamo-cortical sensorimotor loops, causing the classical motor symptoms. Although
the basal ganglia do not receive direct sensory input, they are important for sensorimotor
integration. Therefore, the basal ganglia dysfunction in PD may profoundly affect
sensory-motor interaction in the cortex. Cortical sensorimotor integration can be probed
with transcranial magnetic stimulation (TMS) using a well-established conditioning-test
paradigm, called short-latency afferent inhibition (SAI). SAI probes the fast-inhibitory
effect of a conditioning peripheral electrical stimulus on the motor response evoked by
a TMS test pulse given to the contralateral primary motor cortex (M1). Since SAI occurs
at latencies that match the peaks of early cortical somatosensory potentials, the cortical
circuitry generating SAI may play an important role in rapid online adjustments of cortical
motor output to changes in somatosensory inputs. Here we review the existing studies
that have used SAI to examine how PD affects fast cortical sensory-motor integration.
Studies of SAI in PD have yielded variable results, showing reduced, normal or even
enhanced levels of SAI. This variability may be attributed to the fact that the strength of
SAI is influenced by several factors, such as differences in dopaminergic treatment or the
clinical phenotype of PD. Inter-individual differences in the expression of SAI has been
shown to scale with individual motor impairment as revealed by UPDRS motor score and
thus, may reflect the magnitude of dopaminergic neurodegeneration. The magnitude of
SAI has also been linked to cognitive dysfunction, and it has been suggested that SAI
also reflects cholinergic denervation at the cortical level. Together, the results indicate
that SAI is a useful marker of disease-related alterations in fast cortical sensory-motor
integration driven by subcortical changes in the dopaminergic and cholinergic system.
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Since a multitude of neurobiological factors contribute to the magnitude of inhibition,
any mechanistic interpretation of SAI changes in PD needs to consider the group
characteristics in terms of phenotypical spectrum, disease stage, and medication.
Keywords: short-latency afferent inhibition, cholinergic neuromodulation, cortical oscillations, dopaminergic
dysfunction, Parkinson’s disease, movement disorder, neurophysiological biomarker
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder
affecting multiple neuromodulatory transmitter systems
(Barone, 2010). The cardinal motor symptoms of PD are due to
the progressive loss of nigrostriatal dopaminergic neurons in the
midbrain. Progressive nigrostriatal dopaminergic denervation
causes a dysfunction in the cortex-basal ganglia sensorimotor
loops, producing slowness of movements, rigidity, tremor, and
difficulties with gait and balance (Dickson, 2012). Although the
basal ganglia do not receive direct somatosensory input from
the periphery, several lines of evidence support the idea that
the basal ganglia are important for gating sensory input for
motor control through cortico-basal ganglia-thalamo-cortical
re-entry loops (Haber and Calzavara, 2009). Specifically, primary
and secondary somatosensory cortices in the parietal lobe
send inputs to the striatum of the basal ganglia, where sensory
cortical projections are topographically mapped (Künzle,
1977; Di Martino et al., 2008). The notion that the basal
ganglia are relevant to sensorimotor integration is rather
old. Back in 1985, Lidsky introduced the notion that the basal
ganglia serve as ‘‘sensory analyzer for motor systems’’ which
‘‘ultimately affect movement by gating sensory inputs into
other motor areas’’ (Lidsky et al., 1985). Lesions of the basal
ganglia mostly affect automatic movements that need sensory
guidance, pointing towards a role of the basal ganglia in sensory-
motor control of automatic or highly trained movements
(Boecker et al., 1999).
KEY CONCEPT 1 | Sensorimotor integration
Sensorimotor integration is the process whereby somatosensory input is
integrated by the central nervous system to shape motor program execution.
Parkinson’s disease (PD) is considered a pathological model of aberrant
sensory-motor integration, where movement accuracy and speed are severely
affected by the altered sensory feedback.
In addition, PD patients also exhibit impairment of selecting
the appropriate response while simultaneously suppressing
inappropriate response tendencies (Praamstra and Plat, 2001).
Interestingly, patients with PD display difficulties in suppressing
automatic response activation while proactive inhibitory control
appears to be intact (Praamstra and Plat, 2001; Seiss and
Praamstra, 2004; Wylie et al., 2009). Using transcranial magnetic
stimulation (TMS), it was also shown that impaired inhibition
also manifests itself within the corticomotor output system in
PD (Kleine et al., 2001). The TMS-evoked excitation of the
corticomotor projections produced an increased, prolonged and
less synchronized excitation of the target muscle (Kleine et al.,
2001). This converging evidence shows that anatomical and
functional impairment of the cortico-basal ganglia-thalamo-
cortical loop in PD profoundly affects sensory-motor integration
in the cortex.
Sensorimotor integration at the cortical level can be
probed non-invasively by pairing electrical stimulation of
peripheral somatosensory afferents with focal TMS targeting
the contralateral primary motor cortex (M1). In their seminal
study, Tokimura et al. (2000) demonstrated that peripheral
nerve stimulation at the contralateral wrist reduced the
amplitude of motor evoked potentials (MEPs) when the TMS
pulse was given to the primary motor hand area (M1-
HAND) 2–8 ms after the arrival of the afferent volley in
cortex. The term ‘‘short-latency afferent inhibition’’ (SAI)
was coined for this conditioning-test paradigm, and SAI
soon became a well-established neurophysiological technique
to probe rapid intracortical sensorimotor integration in health
and disease (Turco et al., 2018b). The inhibitory effect
of the sensory input on the motor output provides a
neurophysiological signature of fast sensory-motor integration.
Three components constitute the SAI circuit that enables
fast-integrative processing: the fast afferent-sensory pathway,
the motor-efferent pathway and the integrative component in
the sensorimotor cortex. The neuropharmacological profile of
SAI is complex. The sensory input exerts its inhibitory effects
on the corticospinal neurons through γ-Aminobutyric acid
(GABA)-ergic intracortical circuits (Di Lazzaro et al., 2005c;
Di Lazzaro and Ziemann, 2013), but its magnitude is also
modulated by dopaminergic (Sailer et al., 2003) and cholinergic
neuromodulatory circuits (Di Lazzaro et al., 2000). The fact that
the magnitude of SAI is modulated by cholinergic drugs has
provoked considerable interest in the use of SAI in patients with
dementia. In patients with Alzheimer Disease (AD), a loss of
SAI has been interpreted as an indicator of cortical cholinergic
denervation and a normal SAI as a predictor of a positive effect
of cholinergic medication on cognitive deficits (Di Lazzaro et al.,
2000; Cantone et al., 2014).
KEY CONCEPT 2 | Short-latency afferent inhibition (SAI)
Fast component of sensorimotor integration can be studied in vivo by
examining the effects of sensory input on the motor output at the cortical
level. The amplitude of a motor evoked potential (MEP) induced by transcranial
magnetic simulation (TMS) over the motor cortex is reduced by a peripheral
nerve stimulation few milliseconds before the TMS pulse. The magnitude
of this inhibition represents the neurophysiological correlate of sensorimotor
integration efficiency.
The neurophysiological and neuropharmacological properties
of SAI have motivated researchers to use SAI as a tool to
examine whether and how PD is associated with an impairment
of fast sensory-motor integration in the pericentral sensorimotor
cortex. In the same vein, researchers have examined whether
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the attenuation of SAI in individual patients scales with
dopaminergic and cholinergic cortical neurodegeneration and is
associated with particular clinical symptoms (Martin-Rodriguez
and Mir, 2018). In this review, we first summarize some key
features of SAI in the healthy human brain. We will then review
the evidence for an alteration of SAI in PD and discuss, based
on the published data, whether the individual reduction in SAI
can be used as an electrophysiological biomarker of cholinergic
or dopaminergic denervation of the sensorimotor cortex in PD.
Finally, we will ask the question whether a reduction in SAI is
associated with specific clinical manifestations of PD.
SHORT-LATENCY AFFERENT INHIBITION
IN THE HEALTHY HUMAN BRAIN
Cortical Origin of SAI
Converging evidence supports the hypothesis that SAI is
generated in the sensorimotor cortex, although the exact
anatomic circuits generating SAI are still unknown. The most
direct evidence that peripheral somatosensory input modulates
the TMS-induced motor output at the cortical level comes from
invasive recordings of corticospinal volleys in patients with
implanted electrodes in the cervical epidural space (Tokimura
et al., 2000). These studies showed that later I-waves (I2 and
I3 waves) were reduced at an interval appropriate for SAI,
whereas the early I-wave (I1 wave) remained unchanged. Based
on these findings, it has been proposed that peripheral nerve
stimulation activates glutamatergic thalamocortical projections
onto intracortical GABAA-ergic interneurons which in turn,
suppress the intracortical inhibitory GABAA-ergic circuits
generating the late descending volleys (late I-waves) in the
corticospinal tract (Di Lazzaro and Ziemann, 2013). A critical
role of thalamocortical projections is substantiated by lesion
studies, showing a marked reduction or loss of SAI in patients
with unilateral (Oliviero et al., 2005) or bilateral (Nardone et al.,
2010) paramedian thalamic stroke.
Which Factors Modulate the Expression of
SAI?
The relative strength of SAI depends on the magnitude of the
sensory afferent input evoked by peripheral stimulation. The
greater the afferent volley evoked by peripheral stimulation,
the stronger is the magnitude of SAI (Bailey et al., 2016).
The expression of SAI also depends on the somatotopic
relation between the sensory input and motor output.
Electrical stimulation of digits close to the TMS-target muscle
(i.e., homotopic stimulation) induces stronger inhibition
than stimulation of digits distant to the TMS-target muscle
(i.e., heterotopic stimulation; Classen et al., 2000). The
somatotopic organization of SAI was studied in detail using
a neuronavigated TMSmapping technique which adjusts the coil
position and orientation to the individual shape of the central
sulcus (Dubbioso et al., 2017c). Mapping the input-output
relationship of SAI revealed a center-surround organization
in the human M1-HAND. SAI was evoked by homotopic
stimulation only, whereas the conditioning effect produced the
opposite effect, namely short-latency afferent facilitation (SAF),
in the case of heterotopic stimulation (Dubbioso et al., 2017c).
The expression of homotopic is highly state dependent. In
healthy individuals, SAI is consistently expressed at rest, but
attenuated during finger movements (Dubbioso et al., 2017c).
In the active target muscle, SAI was reduced at movement
initiation during both mixed and homotopic cutaneous nerve
stimulation (Asmussen et al., 2013; Cho et al., 2016), whereas
SAI was reduced during the maintenance phase of the
movement (Asmussen et al., 2013) or found to be normal
(Cho et al., 2016). Accordingly, SAI and SAF by homotopic
or heterotopic stimulation were abolished during the tonic
contraction of the target muscle (Dubbioso et al., 2017c). This
state-dependent pattern of SAI modulation can be attributed
to a sensorimotor gating mechanism, which attenuates the
perceived intensity of stimuli generated bymovements. Although
SAI is closely modulated by movement, no relationship
between SAI magnitude and manual dexterity has been found
(Turco et al., 2018c).
The expression of SAI is not only modulated by the
intrinsic sensorimotor state but also shaped by transcranial
brain stimulation. Transcranial alternating current stimulation
(TACS) at 20 Hz completely abolished SAI in the relaxed muscle
(Guerra et al., 2016). The suppressive effect of 20 Hz TACS on
SAI did not depend on the phase relationship between TACS
and the timing of the TMS pulse probing SAI (Guerra et al.,
2016). This finding suggests a link between SAI expression and
the oscillatory state of the sensorimotor cortex, yet it remains to
be shown that SAI is also suppressed by physiologically generated
beta oscillations in sensorimotor cortex.
The magnitude of SAI can also be modulated by TMS
interventions, for instance when electrical stimulation of the
median nerve is consistently paired with TMS of the contralateral
M1-HAND at an inter-stimulus interval (ISI) of 25 ms
(Quartarone et al., 2006) or with TMS over the contralateral
S1 at an ISI of N20-2.5 ms (Tsang et al., 2015). Sub-motor
threshold 5 Hz repetitive paired associative stimulation produced
a long-lasting increase in corticospinal excitability along with
an attenuation of SAI (Quartarone et al., 2006; Tsang et al.,
2015). Interventional TMS protocols which are thought to induce
homosynaptic plasticity, such as continuous theta burst (cTBS)
have also been sued to modify SAI. While cTBS over M1-HAND
failed tomodulate SAI, cTBS delivered over S1 reduced SAI along
with an increase in cortico-spinal excitability (Tsang et al., 2014).
Cognitive processes, for instance attention and working
memory, shape afferent sensory-motor integration involving
distinct intracortical circuits as demonstrated by single
monophasic TMS pulses that evoke different current directions
in the brain (Mirdamadi et al., 2017; Suzuki and Meehan, 2018).
Specifically, it has been demonstrated that SAI evoked using
antero-posterior (AP), but not posterior-anterior (PA), current
is reduced by a concurrent visual detection task with high
attention demands. These results suggested that only AP-elicited
intracortical circuits are sensitive to cross-modal attention task
by altering sensory processing in premotor areas (Mirdamadi
et al., 2017). Instead, a verbal working memory task modulated
SAI, regardless of the TMS-induced current direction in the
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brain (AP or PA), reflecting a generalized effect of this cognitive
task across anatomically distinct circuits upon cortico-spinal
neurons in the M1-HAND (Suzuki and Meehan, 2018).
The fact that intrinsically and extrinsically induced state
changes in the sensorimotor system can dynamically tune the
expression of SAI needs to be born in mind when SAI is
considered as ‘‘biomarker’’ in PD.
Influence of Neurotransmitter Systems on
SAI Magnitude
Pharmacological and clinical studies provided converging
evidence that the expression of SAI is modulated by several
neurotransmitters such as acetylcholine, dopamine, GABA and
noradrenaline (Turco et al., 2018b). SAI is significantly reduced
by scopolamine, a muscarinic cholinergic antagonist, in young
healthy adults (Di Lazzaro et al., 2000) and can be improved
with rivastigmine, an acetylcholinesterase inhibitor, in patients
with abnormal reduction of SAI, such as AD (Di Lazzaro
et al., 2002). Cholinergic inhibition of pyramidal neurons has
been demonstrated directly in experimental studies (Gulledge
and Stuart, 2005). Interestingly, this rivastigmine effect on SAI
predicted the long term response to cholinesterase inhibitor
in patients with AD (Di Lazzaro et al., 2005a). The effects of
scopolamine and rivastigmine suggest that SAI may be useful
to probe in vivo the functional integrity of central cholinergic
circuits of the human brain. These studies indicate that SAI
can trace the functional impairment of central cholinergic
circuits, allowing to discriminate for example cholinergic from
non-cholinergic form of dementia (Di Lazzaro et al., 2006;
Manganelli et al., 2014; Dubbioso et al., 2017b).
Beyond cholinergic transmission, the dopaminergic system
plays a relevant role in the modulation of SAI, in accordance with
a strong synaptic interaction between dopamine an acetylcholine
signaling in different brain areas (Di Cara et al., 2007; Millan
et al., 2007). L-dopa treatment has been shown to normalize SAI
in patients with restless legs syndrome (Rizzo et al., 2010) and
AD (Martorana et al., 2009; Nardone et al., 2014). Dopaminergic
medication also influences SAI in patients with PD (for more
details see section on PD).
KEY CONCEPT 3 | Dopaminergic medication and sensory processing
Studies on PD patients consistently found reduced levels of SAI in the
ON-medication state suggesting a role of dopamine replacement in driving
this abnormality. Indeed, dopaminergic medication could lead to decreases
in central processing or integration of sensory signals in PD patients. For
instance, it has been shown that dopaminergic medication could worsen
SAI and proprioception. The positive relationship between motor symptoms
and SAI suppression in the ON-medication state suggests that the effect of
medication may be more detrimental to SAI in patients that are less responsive
to dopaminergic pharmacotherapy, for instance, patients with more prominent
cholinergic involvement.
Regarding GABAergic system, in human cortical slices,
it was observed that acetylcholine activated GABA neurons
and triggered GABAergic postsynaptic currents (Alkondon
et al., 2000). Thus, SAI may also be mediated through
the interactions between cholinergic projections and specific
GABAergic interneurons. This also explains the findings that
the administration of positive GABAA but not GABAB receptor
modulators influences SAI (Turco et al., 2018a). Zolpidem, a
selective agonist of alpha1 subunit of GABAA receptor, and
lorazepam, a positive allosteric modulator of GABAA receptor,
significantly reduced SAI (Di Lazzaro et al., 2005b,c, 2007; Turco
et al., 2018a), whereas diazepam, a non-selective agonist, induced
a slight increase or no effect on SAI (Di Lazzaro et al., 2005c,
2007). This observation is presumably explained by a differential
role of the different alpha subunits of GABAA receptor in
the modulation of afferent inhibition with a suppression of
cholinergic inhibition by alpha1 subunit activation.
Lastly, a recent study has also demonstrated that acute
and chronic intake of reboxetine, a noradrenaline reuptake
inhibitor, reduces SAI, likely through suppression of GABAergic
neurotransmission (Kuo et al., 2017).
FAST SENSORY INPUT AND MOTOR
OUTPUT PATHWAYS IN PD
As stated above the basal ganglia do not receive direct sensory
input, yet patients with PD often report sensory symptoms
(Pallis, 1971; Snider et al., 1976; Hillen and Sage, 1996). Objective
somatosensory deficits are well documented in PD and have been
mainly found in tasks that require the use of kinaesthetic sense
such as conscious perception of limb position and motion in
space proprioception and kinaesthesia (Schneider et al., 1987;
Klockgether et al., 1995; Demirci et al., 1997; Jobst et al.,
1997; Zia et al., 2000) or temporal or spatial discrimination
(Conte et al., 2013).
The fast-afferent sensory volley eliciting SAI can be studied by
recording the somatosensory evoked potentials (SSEPs) evoked
by stimulation of the peripheral nerve. Most SSEP studies in
PD have employed electrical stimulation of a mixed nerve
that reflects activation of proprioceptive as well as cutaneous
inputs. SSEP studies in patients with PD found a reduced
amplitude of the late N30 component of the SSEP, while the
early N20-P25 components were found to be normal (Rossini
et al., 1989; Cheron et al., 1994; Ulivelli et al., 1999). SSEP studies
following proprioceptive stimulation during passive flexion
(Mima et al., 1996) or electric stimulation (Restuccia et al., 1999)
of the proximal interphalangeal joint of the finger demonstrated
that the origin of the N30 waveform is more complex than
the early components, containing information from cutaneous
afferents as well as from joint and tendinous inputs. Therefore,
it has been hypothesized that the defective proprioception
described in PD might be related to the depression of the
N30 component.
The early cortical components of the SSEP, namely the dipole
N20/P20 and P25 component, reflect early sensory processing
in the pericentral cortex and are thought to give rise to fast
sensory afferent inhibition. Since these early components are
intact in PD patients, alterations of SAI in PD patients cannot
be attributed to a dysfunction of the afferent sensory pathway.
The same consideration applies to the fast cortico-motor output
pathway which is unaffected in PD. Indeed, a TMS study, which
recorded MEPs at increasing stimulus intensities, demonstrated
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a normal gain function of corticospinal excitability in PD patients
(Kojovic et al., 2012).
However, context-dependent modulation of early cortical
sensory processing is impaired in PD. Normal movement-related
attenuation of perceived stimuli, referred to as sensorimotor
gating, is deficient in patients with PD while they are off
dopaminergic treatment and can be restored by dopamine
replacement therapy (Macerollo et al., 2016). In contrast to
healthy controls, the early N20-P25 SSEP components were
not modulated at all by movement in patients with PD. The
authors speculated that abnormalities in sensory gating may
contribute to the difficulties in movement initiation observed
in PD (Macerollo et al., 2016). Another study on PD patients
treated with deep brain stimulation (DBS) of the subthalamic
nucleus or globus pallidum found that movement of the hand
ipsilateral to median nerve stimulation gated the subcortical
triphasic negative–positive–negative potentials—at latencies of
14–18–22.5 ms, similar to cortical gating observed with SSEP at
N20, P20, and N30 (Insola et al., 2004). Converging evidence
suggests that sensory gating preceding the onset of movement
seems to be mediated by motor cortical areas that contribute to
preparation and execution of movement (Cohen and Starr, 1987;
Seki and Fetz, 2012; Macerollo et al., 2018).
CORTICAL SENSORIMOTOR
INTEGRATION IN PD
Based on the work summarized in the previous sections, it can
be concluded that SAI is a cortical process, albeit the exact circuit
underlying this fast sensory-motor integration is still unknown.
In addition, the lack of major impairment in the fast afferent
sensory-to-cortical and efferent cortical-to-motor pathways in
PD suggest that abnormalities of SAI in PD are caused by a
dysfunction in fast intracortical sensorimotor integration.
Patients with electrodes implanted for DBS provide a unique
opportunity to study the interplay between the subcortical target
site and the cortex. Two electrophysiological studies showed
that continuous high-frequency DBS of the STN modifies SAI
in PD, confirming a close relationship between fast sensory-
motor cortical integration and the basal ganglia. A first study
examined medicated patients with the STN-DBS switched on or
off (Sailer et al., 2007). SAI was reduced in the off-stimulation
and was acutely restored after STN stimulation was resumed,
suggesting that STN stimulation might normalize pathways
that are adversely affected by dopaminergic medications
(Sailer et al., 2007).
A second study focused on the long-term effect of STN-DBS
on SAI and spatial proprioception (Wagle Shukla et al., 2013).
SAI and proprioception were first normalized after 6 months, but
not after 1 month of DBS. This study underscores the importance
of chronic stimulation in the modulation of sensorimotor
integration and proprioception.
The authors considered two possible mechanisms underlying
SAI modulation by STN DBS. High-frequency DBS of the
STN might normalize synchronization between basal ganglia
structures, which might restore the ability of thalamocortical
relay cells to respond to depolarizing inputs involved in
sensorimotor integration (Brown et al., 2001; Rubin and Terman,
2004). Alternatively, STN DBS might have a direct effect
on cortical structures through antidromic stimulation of the
cortico-subthalamic pathway. In addition, the delayed effect
of STN DBS on SAI may reflect long-term plastic changes
in the sensorimotor cortex (Udupa et al., 2016). Whatever
the underlying mechanisms may be, the modulatory effects
of STN-DBS on SAI corroborate a sensorimotor integrative
function of the STN as suggested by animal studies. Many
STN neurons in the monkey (Wichmann et al., 1994) and
patients with PD (Hutchison et al., 1998; Rodriguez-Oroz
et al., 2001; Theodosopoulos et al., 2003) respond to cutaneous
stimuli and passive movements. Alteration of sensory properties
of the STN has been observed in animal models of PD.
Peripheral sensory stimulation by hind paw pinch led to a greater
increase in STN activity in dopamine-depleted rats than controls,
suggesting altered STN sensitivity to afferent sensory inputs in
the parkinsonian state (Magill et al., 2001).
IS SAI ABNORMAL IN PD?
To answer this question, we conducted a literature search on
Pubmed1 using the following search strings: ‘‘Short afferent
inhibition’’ OR ‘‘SAI’’ AND ‘‘PD.’’
Exclusion criteria were as follows:
i. review articles or letter to the editors reporting no original
data.
ii. studies about atypical parkinsonism [i.e., Progressive
Supranuclear Palsy (PSP), Multisystemic Atrophy or Cortical
Basal Syndrome], or dystonia not including PD population as
control group.
This search resulted in 22 studies on the final search on
November 2, 2018 (Tables 1, 2). Fourteen studies reported
a reduction of SAI in patients with PD. The average disease
duration was 6.14 ± 4.39 years, mean ON UPDRS-III score
was 24.03 ± 13.11, and the mean L-dopa equivalent dose
667.02 ± 314.51 mg across all positive studies (Table 1). In the
remaining eight studies, six reported normal (Degardin et al.,
2012; Zamir et al., 2012; Picillo et al., 2015; Dubbioso et al.,
2017a; Ponzo et al., 2017; Nelson et al., 2018) and two found an
enhanced SAI in PD patients (Di Lazzaro et al., 2004; Nardone
et al., 2005). Mean disease duration was 5.63 ± 2.69 years, mean
ON UPDRS-III score was 18.32 ± 8.52 and L-dopa equivalent
dose was 633.94± 206.30mg across all negative studies (Table 2).
Importantly, these studies found consistent reduction of SAI
mainly in medicated PD patients, whereas the off state was
not associated with SAI alterations. The idea that nigrostriatal
dopaminergic denervation does not reduce SAI or might even
enhance cortical inhibition is supported by two studies. The
first one, a small study on three drug-free patients with pure
hemiparkinsonism (Di Lazzaro et al., 2004) showed enhanced
SAI on the affected side. The second one, performed on 10 PD
patients in off-state confirmed the increased cortical inhibition
respect to patients with PSP and healthy controls (Nardone et al.,
1https://www.ncbi.nlm.nih.gov/pubmed/
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2005). The enhancement of SAI in the affected side might be
related to an increase of cholinergic muscarinic activity in the
contralateral cerebral cortex. Altered muscarinic cortical activity
in PD is also supported by several post-mortem studies that have
shown an increase in the total number of muscarinic cholinergic
receptors in the cerebral cortex (Ruberg et al., 1982; Sirviö et al.,
1989; Lange et al., 1993).
An intriguing and alternative hypothesis might be that
a reduced thalamo-cortical drive caused by nigrostriatal
dopaminergic denervation may increase SAI, an effect which
might be obscured by chronic dopamine replacing therapy.
In 2003, Sailer et al. (2003) systematically examined the
effect of dopaminergic therapy in 10 PD patients on and off
medication. Patients only showed a reduction in SAI when they
were on medication, and the medication-induced reduction in
SAI only emerged on the more affected side. The medication-
related SAI reduction can be restored acutely with STN-DBS
(Sailer et al., 2007). This finding was largely confirmed by a
recent meta-analysis which only found a consistent reduction
in SAI across studies for PD patients on medication, but the
attenuating effect of medication on SAI in PD was retrieved
in the meta-analysis regardless of the affected side (Martin-
Rodriguez and Mir, 2018). Moreover, the meta-analysis revealed
an association between SAI changes and disease severity as
well as cognitive deficits. Specifically, SAI impairment scaled
with cognitive deficits in the four major cognitive domains,
although the strongest association was found for visuospatial and
executive deficits.
Prompted by these findings, we pooled SAI data from our
database and three previous studies (Manganelli et al., 2009;
Picillo et al., 2015; Dubbioso et al., 2017a). The pooled data
set included measurements from 81 PD patients (57 men)
with a mean age of 64.37 ± 7.57 years, average disease
duration of 8.41 ± 4.61 years, mean ON UPDRS-III score
of 15.48 ± 10.89, and a daily L-dopa equivalent dose of
833.55 ± 470.70 mg. SAI was tested in all patient on the more
affected side while they were taking their normal medication.
SAI measurements covered five interstimulus intervals adjusted
to the individual N20 wave latency (N20+0 ms, N20+2 ms,
N20+4 ms, N20+6 ms, N20+8 ms). Patient’s UPDRS III motor
score in the ON medication state was the only variable that
showed a positive linear correlation with SAI at an ISI of
N20+4 ms (ρ = 0.405; p < 0.01) and with the mean SAI
across all five interstimulus intervals (ρ = 0.401; p < 0.01,
Figures 1A,B). Indeed, neither disease duration nor daily
dopaminergic medication showed a significant relationship with
SAI (all p ≥ 0.105). Overall, the results suggest that the
attenuating effect of medication state on SAI is more pronounced
in patients in whom dopamine replacement therapy shows
limited efficacy to normalize parkinsonian motor symptoms
as indicated by high UPDRS scores in the on-medication
state. It is conceivable that patients who show a less favorable
FIGURE 1 | Analysis of short-latency afferent inhibition (SAI) in our Parkinson’s Disease (PD) cohort and schematic representation of cholinergic sources in the
human brain with their clinical correlates in PD. (A) Temporal evolution of SAI in our cohort of PD patients. The horizontal axis shows inter-stimulus interval (ISI) values
(the time between the peripheral stimulation and cortical stimulation). ISIs were determined by adding 0, 2, 4, 6, and 8 ms to the latency of the N20 component. The
vertical axis shows the percentage of test motor evoked potential (MEP) at each ISI. (B) Linear positive correlation between SAI at ISI N20+4 ms, Grand-Mean SAI
and UPDRS III motor score in medicated patients. (C) Schematic representation of the three major sources of cholinergic projections in the brain and main clinical
correlates in PD (red boxes). Basal forebrain neurons, including the nucleus basalis of Meynert (nbM), medial septal nucleus (MS) and diagonal band of Broca (DB)
provide the cholinergic projections to the cerebral cortex and are responsible for cognitive impairment, gait impairment and psychosis. The pedunculopontine
nucleus-laterodorsal tegmental complex [referred to as the pedunculopontine tegmental nucleus (PPN) and LDT], a brainstem center, provides cholinergic inputs
primarily to the thalamus, but also has connections to the cerebellum, several brainstem nuclei, some striatal fibers, and the spinal cord. This system is mainly
involved in walking disturbances, rem-sleep behavior disorders (RBDs) and psychosis. In addition, small populations of intrinsic cholinergic neurons are present in the
hippocampus, striatum (cholinergic interneurons), parts of the reticular formation, and cerebellum. The cholinergic interneurons might be the main cause of motor
symptoms in PD.
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response to dopamine replacement therapy may also have more
cholinergic deficits and hence the reduction in SAI may, at least
in part, resulting from a co-existing cholinergic deficit at the
cortical level. Interestingly, patients with atypical parkinsonism
(i.e., Progressive Supranuclear Palsy or Multisystemic Atrophy)
that usually respond insufficiently to dopaminergic medication,
might exhibit reduced levels of SAI (Brusa et al., 2014;
Celebi et al., 2014).
DOES SAI IN PD SCALE WITH GAIT
PROBLEMS AND NON-MOTOR
SYMPTOMS?
PD causes a wide range of non-motor symptoms which may
even precede the manifestation of the classic motor symptoms
(Riedel et al., 2010). Non-motor symptoms include cognitive
dysfunctions and decline, apathy, psychiatric disturbances
(depression, psychosis, impulse control), autonomic failure
(gastrointestinal, cardiovascular, urinary, sexual ability,
thermoregulation), sleep disorders, and pain syndrome
(Chaudhuri and Schapira, 2009). In recent years, SAI has
been increasingly used in PD to identify whether specific
motor and non-motor symptoms scale with abnormalities
in SAI, presumably due to cholinergic and dopaminergic
cortical dysfunction.
KEY CONCEPT 4 | Motor and non-motor symptoms
Sources of considerable burden in people with PD are the typical
motor symptoms, such as resting tremor, rigidity, bradykinesia, postural
instability and non-motor symptoms, namely cognitive declines, psychiatric
disturbances, autonomic failures, sleep difficulties, and pain syndrome.
These symptoms are variously associated with dopaminergic/cholinergic
neurodegeneration and SAI alteration at the cortical level.
Among motor disturbances, gait abnormalities and falls have
attracted attention for their association with cognitive decline
and cholinergic dysfunction in PD (Newman et al., 2012; Perez-
Lloret and Barrantes, 2016). Indeed, reduced SAI has been
proven to be an independent predictor of slower gait speed
(Rochester et al., 2012) and associated with a higher falls risk in
PD (Pelosin et al., 2016). However, in a recent study performed
on PD with freezing of gait (FOG; Picillo et al., 2015) the authors
failed to prove alteration of SAI in this subtype of patients.
Since gait disturbances in PD are heterogeneous and may be
underpinned by different neurotransmitters and circuits, it is to
be expected that the relation between SAI and gait deficits may be
complex and the modulatory role of medication state also needs
to be factored in when addressing this issue.
Regarding non-motor symptoms, SAI abnormalities have
been found associated with dementia and Mild Cognitive
Impairment (MCI; Celebi et al., 2012; Yarnall et al., 2013),
confirming the role of cholinergic dysfunction in the
development of cognitive impairment in PD. Indeed, SAI
has been found to be reduced in PD patients with those
symptoms associated with a higher risk of cognitive decline, such
as visual hallucinations (VH; Manganelli et al., 2009), dysphagia
(Lee et al., 2015), olfactory dysfunction (Oh et al., 2017; Versace
et al., 2017) and REM-sleep Behavior Disorders (RBDs; Nardone
et al., 2013). These studies are in agreement with the idea that
the cholinergic dysfunction makes a major contribution to
non-motor symptoms and associated cognitive deficits in PD
(Marra et al., 2012; Newman et al., 2012).
A recent review summarized central cholinergic sources
of the healthy human brain in two main tracks (Newman
et al., 2012). On the one hand, brainstem nuclei, including
the pedunculopontine tegmental nucleus (PPN) and the
laterodorsal pontine tegmentum, send cholinergic projections
to the thalamus, basal ganglia, basal forebrain and to a much
lesser extent, the cerebral cortex. On the other hand, the
magnocellular basal forebrain-cholinergic systems, including
the nucleus basalis magnocellularis and nucleus basalis
of Meinert (NBM) send major projections to neocortex,
entorhinal cortex, limbic cortices, cingulate cortex, and
hippocampus. In addition, small populations of intrinsic
cholinergic neurons are present in the hippocampus, striatum
(cholinergic interneurons), parts of the reticular formation,
and cerebellum (Bohnen and Albin, 2011; Manganelli et al.,
2013; Dubbioso et al., 2015). These cholinergic nuclei and
their projections have selectively degenerated in PD (Bohnen
and Albin, 2011; Perez-Lloret and Barrantes, 2016). Thus,
we speculate that SAI in PD may mainly reflect a cortical
cholinergic deficit due to cholinergic neurodegeneration. The
cortical cholinergic imbalance may derive from many sources
that are variably impaired according to disease severity and
symptoms. For example, degeneration of cholinergic striatal
tone is responsible for motor symptoms, alteration of the NBM
and/or PPN nuclei for gait impairment and falls, cognitive
decline, RBD, psychosis (Perez-Lloret and Barrantes, 2016),
see Figure 1C.
CONCLUSION AND OUTLOOK
In this review, we have discussed the possible contributions of the
fast-afferent somatosensory pathway, the intracortical integrative
component and the fast-efferent corticomotor pathway to
alterations of SAI in PD. We concluded that PD-related changes
in SAI are most likely caused at the cortical level, where sensory
input is rapidly integrated into a motor output. This makes SAI
a useful tool to probe how PD impacts on the sensorimotor
integration processing at the cortical level.
Studies performed on PDpatients have shown variable results,
ranging from reduced to normal or even enhanced SAI findings.
Several factors may be responsible for these heterogenous results
such as between-group differences in disease severity, disease
duration, dopamine replacement therapy and cognitive status.
While patients with PD show normal levels of SAI in the
off-medication state, SAI is reduced in the on-medication state,
suggesting a role of dopamine replacement in driving this
abnormality. Interestingly, previous research has suggested that
dopaminergic medication could lead to decreases in central
processing or integration of sensory signals in PD patients.
For instance, it has been shown that dopaminergic medication
could worsen SAI and proprioception (distal and spatial errors)
and were normalized by chronic STN-DBS, likely through
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long-term plastic changes in the basal ganglia thalamocortical
circuit (Wagle Shukla et al., 2013). Yet, pharmacological studies
which systematically study dose-dependent effects of dopamine
replacement therapy on SAI magnitude in PD are still lacking.
The positive relationship between residual parkinsonian motor
symptoms and SAI suppression in the on-medication state
suggests that the effect of dopamine replacement may be more
detrimental to SAI in patients that are less responsive to
dopaminergic pharmacotherapy, for instance, patients withmore
prominent cholinergic involvement. This would also explain why
non-motor symptoms have been associated with a reduction of
SAI in PD.
Some important aspects of SAI still remain to be explored
in PD. For instance, by systematically varying the intensity
of peripheral stimulation one may derive a stimulus-response
curve of SAI that may be more sensitive to intrinsic disease-
related but also therapy-related changes in SAI. Furthermore,
the application of homotopic or heterotopic somatosensory
stimulation may reveal interesting insights into the altered
center-surround organization of fast sensorimotor integration at
the cortical level (Dubbioso et al., 2017c).
Future research on SAI in PD should focus on validating
SAI as a biomarker of central cholinergic activity through a
multimodal approach by combining neurophysiological results
with neuroimaging. For example, correlation analysis with
structural data (i.e., analysis of gray matter volume, diffusion
tensor imaging) of the main cholinergic system nuclei, would
reveal a structure-function relationship between SAI changes
and structural cholinergic denervation. The introduction of new
PET radioligands, such as (18 F) fluoroethoxybenzoyesamicol
[(18 F) FEOBV], a ligand which shows a high affinity for the
vesicular acetylcholine transporter, will enable the researcher to
simultaneously examine functional changes of the cholinergic
system in vivo. This line of research will help to clarify the role
of impaired cholinergic neurotransmission in the development
of motor and non-motor symptoms in PD.
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